Previous 10 | Next 10 |
2023-07-27 10:07:10 ET Gainers: Carmell Therapeutics ( CTCX ) +44% . Mallinckrodt ( MNK ) +35% . Evolus ( EOLS ) +28% . Lipocine ( LPCN ) +26% . Spok ( SPOK ) +23% . Losers: Mersana Therapeutics ( MRSN ) -77% . ...
2023-07-27 08:38:02 ET Mersana Therapeutics ( MRSN ) -74% announces topline data from UPLIFT clinical trial in patients with platinum-resistant Ovarian Cancer and strategic reprioritization. Biohaven ( BHVN ) -27% . Yellow Corporation ( YELL ) -26% . ...
UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces expenses to extend cash runway into 2026 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:...
2023-07-26 23:18:28 ET Summary Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. NTLA is on track toward key data and regulatory catalysts. Early clinical data in HAE and ATTR have provided solid validation for Intellia's...
2023-07-25 18:21:53 ET Gainers: PacWest Bancorp ( PACW ) +38% . PacWest Bancorp ( PACWP ) +15% . Tenable Holdings ( TENB ) +9% . DISH Network ( DISH ) +7% . WW International ( WW ) +7% . Losers: Encore Wire ( ...
2023-07-22 03:21:52 ET Summary Mersana Therapeutics' stock price has had a turbulent year, with shares soaring over 100% before plummeting by 60% due to failure to demonstrate clinical benefits in ongoing studies. The recent clinical hold and Grade 5 bleeding events raised serious...
2023-07-12 10:45:16 ET Summary bluebird works as a biotech company developing curative gene therapies to save lives. Concerns over its cash runway and clinical trials are overblown, with the stock near all-time lows. Near-term catalysts from Lovo-cell, Zynteglo, and Skysona ar...
2023-06-27 17:26:51 ET Gainers: Geospace Technologies ( GEOS ) +7% . AeroVironment ( AVAV ) +6% . Codexis ( CDXS ) +5% . Recursion Pharmaceuticals ( RXRX ) +3% . CECO Environmental ( CECO ) +3% . Losers: AST SpaceMo...
SAN FRANCISCO, June 20, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Mersana Therapeutics, Inc. (NASDAQ: MRSN) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/MRSN Contact An Attorney Now: MRSN@hbsslaw.com ...
SAN FRANCISCO, CA / ACCESSWIRE / June16, 2023 / Hagens Berman urges Mersana Therapeutics, Inc. (NASDAQ:MRSN) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/MRSN Contact An Attorney Now: MRSN@hbsslaw.com 844-916-0895 M...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...